Anatol Kreitzer, Chief Discovery Officer, sold 12,248 shares of MapLight Therapeutics, Inc. at $7.84 a share, worth $96K in total on Oct 15, 2026. Shares held after the trade: 168,678 (-6.8%).
MapLight Therapeutics CMO Erin Pennock Foff Sells $124K of Stock
Erin Pennock Foff, CMO, sold 15,355 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $124K in total on Oct 15, 2026. Shares held after the trade: 296,906 (-4.9%).
MapLight Therapeutics General Counsel Kristopher Hanson Sells $72.9K of Stock
Kristopher Hanson, General Counsel, sold 9,020 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $72.9K in total on Oct 15, 2026. Shares held after the trade: 128,024 (-6.6%).
MapLight Therapeutics CAO and Interim CFO Jonathan Gillis Sells $82.1K of Stock
Jonathan Gillis, CAO and Interim CFO, sold 10,167 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $82.1K in total on Oct 15, 2026. Shares held after the trade: 142,315 (-6.7%).
MapLight Therapeutics CSO James Woodruff Lillie Sells $93K of Stock
James Woodruff Lillie, CSO, sold 11,513 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $93K in total on Oct 15, 2026. Shares held after the trade: 198,597 (-5.5%).
MapLight Therapeutics CEO Christopher A. Kroeger Sells $595K of Stock
Christopher A. Kroeger, CEO, sold 73,691 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $595K in total on Oct 15, 2026. Shares held after the trade: 1,195,909 (-5.8%).
MapLight Therapeutics General Counsel Kristopher Hanson Sells $193K of Stock
Kristopher Hanson, General Counsel, sold 16,509 shares of MapLight Therapeutics, Inc. at $11.67 a share, worth $193K in total on Sep 16, 2026. Shares held after the trade: 137,044 (-10.8%).